Effect of High-intensity Statin Treatment on Prognosis of Patients with Early-onset Coronary Heart Disease who Underwent Direct PCI after STEMI
Objective:To analyze the clinical effect of high-intensity statin treatment in the treatment of early-onset coronary heart disease acute ST-segment elevation myocardial infarction(STEMI).Method:A total of 130 patients with acute SETMI with early-onset coronary heart disease who were hospitalized in the Department of Cardiology,Jiugang Hospital from January 2021 to January 2023 were selected as the study objects.After direct percutaneous coronary intervention(PCI),they were randomly divided into experimental group(n=63)and control group(n=67).Both groups were given conventional basic treatment,the experimental group was given Rosuvastatin Calcium Tablets 20 mg/d,the control group was given Rosuvastatin Calcium Tablets 10 mg/d,continuous administration for 12 months.Blood lipid indexes,cardiac function indexes,incidence of adverse drug reactions,incidence of major adverse cardiovascular events(MACE),TIMI blood flow grade,incidence of intra-stent restenosis(ISR)of coronary artery,and coronary slow flow phenomenon(CSFP)in the two groups were observed.Result:After treatment,total cholesterol(TC)and low density lipoprotein cholesterol(LDL-C)in two groups were lower than those before treatment,triglyceride(TG)in experimental group was lower than that before treatment,and high density lipoprotein cholesterol(HDL-C)was higher than that before treatment,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse drug reactions between the two groups(P>0.05).There was no significant difference in the incidence of MACE between the two groups(P>0.05).There were no significant differences in TIMI blood flow grading and incidence of ISR between the two groups(P>0.05),and the proportion of CSFP patients in the experimental group was lower than that in the control group,the differences were statistically significant(P<0.05).Conclusion:High-intensity Rosuvastine treatment has a certain protective effect on infarct-related artery(IRA)in patients with early-onset coronary heart disease and SETMI.The adverse drug reactions were comparable to the standard dose,and the safety was good.
国家科技期刊平台
NSTL
万方数据
维普
